Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICT vs NCRT in Locally Advanced Esophageal Cancer
NCT07236320Completed
- Start
- Mar 2018
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of camrelizumab and toripalimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms). Primary endpoints: Overall Survival at 5 years and Disease-Free Survival at 5 years. Started Mar 2018; status: completed.
02
Drugs
camrelizumabtoripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07236320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07236320.